Nov 25 (Reuters) - Biohaven said on Monday its experimental treatment for spinal muscular atrophy, a rare nervous system dosorder, helped improve patients' motor function in a late-stage study, but failed to achieve statistical significance compared to placebo and standard of care.

(Reporting by Mariam Sunny in Bengaluru; Editing by Arun Koyyur)

((Mariam.ESunny@thomsonreuters.com;))